Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers

BACKGROUND: We aimed to determine the safety and efficacy of nintedanib, an oral anti-angiogenic tyrosine kinase inhibitor, in combination with pembrolizumab, an anti-PD1 immunotherapy, in patients with advanced solid tumors (PEMBIB trial; NCT02856425). METHODS: In this monocentric phase Ib dose esc...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldini, Capucine, Danlos, Francois-Xavier, Varga, Andreea, Texier, Matthieu, Halse, Heloise, Mouraud, Severine, Cassard, Lydie, Champiat, Stéphane, Signolle, Nicolas, Vuagnat, Perrine, Martin-Romano, Patricia, Michot, Jean-Marie, Bahleda, Rastislav, Gazzah, Anas, Boselli, Lisa, Bredel, Delphine, Grivel, Jonathan, Mohamed-Djalim, Chifaou, Escriou, Guillaume, Grynszpan, Laetitia, Bigorgne, Amelie, Rafie, Saloomeh, Abbassi, Alae, Ribrag, Vincent, Postel-Vinay, Sophie, Hollebecque, Antoine, Susini, Sandrine, Farhane, Siham, Lacroix, Ludovic, Parpaleix, Aurelien, Laghouati, Salim, Zitvogel, Laurence, Adam, Julien, Chaput, Nathalie, Soria, Jean-Charles, Massard, Christophe, Marabelle, Aurelien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260998/
https://www.ncbi.nlm.nih.gov/pubmed/35794623
http://dx.doi.org/10.1186/s13046-022-02423-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260998/
https://www.ncbi.nlm.nih.gov/pubmed/35794623
http://dx.doi.org/10.1186/s13046-022-02423-0

Ejemplares similares